Evidence map›Paper›PMID 41665676›Full record

Observational studyEuropean journal of nuclear medicine and molecular imaging2026

Impact of radium-223 on bone imaging and biochemical markers with and without bone-modifying agents in bone-metastatic castration-resistant prostate cancer: results from the kyucog-1901 study.

Masaki Shiota, Hideki Enokida, Yoji Murakami, Toshiyuki Kamoto, Tsukasa Igawa, Naoya Masumori, Hirotsugu Uemura, Kensuke Mitsunari, Takayuki Sumiyoshi, Hiroji Uemura and 5 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Masaki ShiotaDepartment of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan. shiota.masaki.101@m.kyushu-u.ac.jp.ORCID 0000-0002-3306-4858
Hideki EnokidaDepartment of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
Yoji MurakamiDepartment of Urology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Toshiyuki KamotoDepartment of Urology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Tsukasa IgawaDepartment of Urology, School of Medicine, Kurume University, Kurume, Japan.
Naoya MasumoriDepartment of Urology, School of Medicine, Sapporo Medical University, Sapporo, Japan.
Hirotsugu UemuraDepartment of Urology, Faculty of Medicine, Kindai University, Osaka-Sayama, Japan.
Kensuke MitsunariDepartment of Urology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Takayuki SumiyoshiDepartment of Urology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Hiroji UemuraDepartment of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan.
Katsuyoshi HigashijimaDepartment of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Shoji TokunagaClinical Therapeutic Trial Center, Ehime University Hospital, Ehime, Japan.
Takuro IsodaDepartment of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Kousei IshigamiDepartment of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Masatoshi EtoDepartment of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRadium-223 dichloride (Ra-223) improves survival in men with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases, but its interaction with bone-modifying agents remains unclear.

methodsThe KYUCOG-1901 prospective multicenter study enrolled Japanese men with mCRPC and bone metastases treated with up to six cycles of Ra-223. Serial assessments included bone scan index (BSI), serum bone metabolic markers (BMMs; BAP, P1NP, and TRACP-5b), and bone mineral density (BMD) from baseline (BL) through one year. Clinical outcomes including radiographic progression-free survival (rPFS), time to symptomatic skeletal event and overall survival were assessed by BSI and serum BMMs.

resultsBSI remained stable throughout treatment and follow-up. High BL BSI predicted early discontinuation and shorter rPFS, and increases in BSI correlated with worse rPFS. BAP exhibited a transient decline in patients treated with and without bone-modifying agents (BMAs), while TRACP-5b declined in those receiving BMAs. Elevated BAP at BL and BMMs at end of treatment, and increases in P1NP during therapy, were associated with rPFS. Lumbar spine BMD increased modestly over 1 year in both patients treated with and without BMAs, while femoral BMD remained unchanged.

conclusionRa-223 stabilized skeletal tumor burden, transiently suppressed serum BMMs, and improved lumbar BMD in men with mCRPC. BSI and serum BMMs provided prognostic information, supporting their integration into longitudinal monitoring. These findings highlight the potential of combining Ra-223 with bone-modifying agents to optimize outcomes.

Indexed as

Biomarkers, TumorBone and BonesBone NeoplasmsProstatic Neoplasms, Castration-ResistantRadiumAgedBone DensityHumansMaleMiddle AgedRadioisotopesTreatment OutcomeBiomarkers, TumorRadioisotopesRadiumRadium-223radium Ra 223 dichlorideBone metabolic markerBone mineral densityBone scan indexProstate cancerRadium-223

Identifiers

PMID41665676
PMCPMC13197349

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.